| Name | Title | Contact Details |
|---|
BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies.
ParagonRx is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Landos pursues safer, more effective first-in-class oral therapeutics for autoimmune disorders at an accelerated rate.
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.